drugset / Trial / NCT00234507
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
Timeline
- Start
- 2003-01
- Primary completion
- 2004-05-25
- Completion
- 2004-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 40 iu | Subcutaneous |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 80 iu | Subcutaneous |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 120 iu | Subcutaneous |